Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Anthony Declusin

Concepts (11)

Concepts are derived automatically from a person's publications.

The timeline below shows the dates (blue tick marks) of publications associated with Anthony Declusin's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that Anthony Declusin has written about over time.
Autoantibodies, 1 publications between 2023 and 2023, average publication date January 2023. Immunoglobulin G, 1 publications between 2023 and 2023, average publication date January 2023. Multiple Sclerosis, 1 publications between 2023 and 2023, average publication date January 2023. Myelin-Oligodendrocyte Glycoprotein, 1 publications between 2023 and 2023, average publication date January 2023. Neuromyelitis Optica, 1 publications between 2023 and 2023, average publication date January 2023. Humans, 2 publications between 2023 and 2023, average publication date April 2023. Antibodies, Antinuclear, 1 publications between 2023 and 2023, average publication date June 2023. Diplopia, 1 publications between 2023 and 2023, average publication date June 2023. Dystonia, 1 publications between 2023 and 2023, average publication date June 2023. Laryngismus, 1 publications between 2023 and 2023, average publication date June 2023. Paraneoplastic Syndromes, Nervous System, 1 publications between 2023 and 2023, average publication date June 2023.

To see the data from this visualization as text, click here.
Declusin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)